Nebenwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.8 · PDF-Seite 23–24
HOS-089978 · Präparat HOS-083949
23 Immune system disorders Rare Angioedema Hepatobiliary disorders Very common ALT elevations (see section 4.4) Exacerbations of hepatitis, primarily detected by serum ALT elevations, have been reported ‘on-treatment’ and following lamivudine withdrawal. Most events have been self-limited, however fatalities have been observed very rarely (see section 4.4). Skin and subcutaneous tissue disorders Common Rash, pruritus Musculoskeletal and connective tissue disorders Common Elevations of CPK Common Muscle disorders, including myalgia and cramps* Not known Rhabdomyolysis * In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 653544f29f133189a86859c2904aab713ddcaf0c652c033aee1779b3e7fc0eaf · Zeichen 1300–2116 im Abschnitt